This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Snowden JA, Ahmedzai SH, Cox A, Cairns DA, Ashcroft J, Williams C, et al. Association of genetic variants with patient-reported quality of life and pain experience in patients in the UK NCRI myeloma X relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplant. 2022:Online ahead of print.
Virtue G. Avengers 4 trailer: five things we learned about Marvel’s Endgame movie. The Guardian. 2018
Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797–804.
Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guerin-Charbonnel C, Ferrer L, et al. A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in European patients with multiple myeloma. Clin Cancer Res. 2016;22:4350–5.
Garcia-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jimenez C, Prieto I, et al. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematol Oncol. 2017;35:746–51.
Mahmoudpour SH, Bandapalli OR, da Silva Filho MI, Campo C, Hemminki K, Goldschmidt H, et al. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients. BMC Cancer. 2018;18:820.
Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340–e51.
Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, et al. Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. J Clin Oncol. 2019;37:1617–28.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–20.
Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, et al. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015;121:1138–46.
Kim H, Ramsay E, Lee H, Wahl S, Dionne RA. Genome-wide association study of acute post-surgical pain in humans. Pharmacogenomics. 2009;10:171–9.
Mulik A, Novochadov V, Bondarev A, Lipnitskaya S, Ulesikova I, Shatyr Y. New insights into genotype-phenotype correlation in individuals with different level of general non-specific reactivity of an organism. J Integr Bioinform. 2016;13:295.
Peters MJ, Broer L, Willemen HL, Eiriksdottir G, Hocking LJ, Holliday KL, et al. Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the 5p15.2 region. Ann Rheum Dis. 2013;72:427–36.
Hulin C, Hansen T, Heron L, Pughe R, Streetly M, Plate A, et al. Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leuk Res. 2017;59:75–84.
RB reports: Curio Science: Honoraria; Eradigm Consulting: Consulting; Guidepoint Global: Consulting; i3 Health, Honoraria; Pack Health: Research Funding; Sanofi Pasteur: Consulting; SparkCures: Consulting. NS reports: Bluebird Bio: Research Funding; GSK: Consultancy; Janssen: Research Funding; Indapta Therapeutics: Consultancy; BMS/Celgene: Research Funding; CareDx: Consultancy; CSL Behring: Consultancy; Kite: Consultancy; Nektar: Research Funding; Karyopharm: Consultancy; Amgen: Consultancy; Oncopeptides: Consultancy; Poseida: Research Funding; Precision Biosciences: Research Funding; Sanofi: Consultancy; Sutro Biopharma: Research Funding; Teneobio: Research Funding.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Banerjee, R., Shah, N. SNPs and PROs in myeloma: the most ambitious crossover of all time?. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01732-4